Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention
Giampaolo Niccoli(University of Parma), Filippo Crea(Università Cattolica del Sacro Cuore), Fabio M. Pulcinelli(Sapienza University of Rome), Luigi M. Biasucci(Agostino Gemelli University Polyclinic), Eleonora Russo(Università Cattolica del Sacro Cuore), Antonio Maria Leone(Agostino Gemelli University Polyclinic), Italo Porto(University of Genoa), Francesco Burzotta(Agostino Gemelli University Polyclinic), Angelo Di Leo(Hospital of Prato), Silvia Riondino(Sapienza University of Rome), Simona Giubilato(Università Cattolica del Sacro Cuore), Cristina Spaziani(Università Cattolica del Sacro Cuore)
Cited by 72
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Optical coherence tomography in coronary atherosclerosis assessment and intervention
|Nature Reviews Cardiology|2022|397
Aspirin resistance: position paper of the Working Group on Aspirin Resistance
|Journal of Thrombosis and Haemostasis|2005|329
OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
|New England Journal of Medicine|2023|322